BeOne Medicines (BEIGF) EBIT Margin (2016 - 2025)
Historic EBIT Margin for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to 11.55%.
- BeOne Medicines' EBIT Margin rose 235600.0% to 11.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.67%, marking a year-over-year increase of 299800.0%. This contributed to the annual value of 14.91% for FY2024, which is 342100.0% up from last year.
- According to the latest figures from Q3 2025, BeOne Medicines' EBIT Margin is 11.55%, which was up 235600.0% from 6.68% recorded in Q2 2025.
- In the past 5 years, BeOne Medicines' EBIT Margin registered a high of 89.06% during Q4 2021, and its lowest value of 316.58% during Q2 2021.
- In the last 5 years, BeOne Medicines' EBIT Margin had a median value of 34.77% in 2024 and averaged 63.67%.
- Its EBIT Margin has fluctuated over the past 5 years, first surged by 7295300bps in 2021, then tumbled by -2123500bps in 2022.
- Quarter analysis of 5 years shows BeOne Medicines' EBIT Margin stood at 89.06% in 2021, then plummeted by -238bps to 123.29% in 2022, then skyrocketed by 51bps to 60.5% in 2023, then soared by 88bps to 7.04% in 2024, then soared by 264bps to 11.55% in 2025.
- Its EBIT Margin stands at 11.55% for Q3 2025, versus 6.68% for Q2 2025 and 0.99% for Q1 2025.